March 31, 2021 Webinar: Our IWMF experts will share an update on the status of existing vaccines and others in development. This interactive LIVE question and answer session will explain side effects and recommendations for WM patients.

Stephen M. Ansell, MD, PhD, is a consultant in the Division of Hematology, Department of Internal Medicine at Mayo Clinic in Minnesota. Dr. Ansell currently serves as chair of the Mayo Clinic Lymphoma Disease-Oriented Group and chair of faculty development and recruitment for the Division of Hematology. He joined the staff of Mayo Clinic in 1999 and holds the academic rank of professor of medicine, Mayo Clinic College of Medicine and Science.

Dr. Ansell earned his MB, ChB, and PhD degrees at University of Pretoria in Pretoria, South Africa, where he also completed an internship in internal medicine and surgery, a residency in internal medicine, and a fellowship in medical oncology. Dr. Ansell continued his education at University of the Witwatersrand in Johannesburg where he was a registrar in internal medicine. He then came to the United States and completed a residency in internal medicine and then a fellowship in hematology/oncology at Mayo Clinic. Dr. Ansell’s research focuses on investigating the phenotype and activity of intratumoral T-cells and developing strategies to modulate the T-cell infiltration in B-cell lymphoma.

Jorge J. Castillo, MD, is Associate Professor at Harvard Medical School and Clinical Director of the Bing Center for Waldenström Macroglobulinemia at Dana-Farber Cancer Institute.

Dr. Castillo was born in Peru and received his medical degree at the Universidad Autonoma Metropolitana in Mexico City. He completed his residency in internal medicine at the University of Massachusetts and his fellowship in hematology and medical oncology at Brown University.

Dr. Castillo specializes in the treatment of Waldenström macroglobulinemia. His research focuses on the various risk factors associated with an increased risk of developing hematologic malignancies. He currently is the principal investigator in a series of innovative clinical trials evaluating highly effective non-chemotherapeutic approaches for patients with Waldenström macroglobulinemia. Dr. Castillo has authored more than 220 peer-reviewed articles and has published his research in The New England Journal of Medicine, Lancet Oncology, Journal of Clinical Oncology and Blood.

Dr. Castillo is a member of several professional organizations, including the American Society of Hematology, and the Peruvian Society of Hematology (honorary). He regularly contributes to the International Workshop on Waldenström Macroglobulinemia, serving on task forces and scientific program committees for the annual meeting. He also is an advisor to the Steering Committee for the Latin American Group for the Study of Lymphoma.

Dr. Castillo is a member of the NCCN Multiple Myeloma/Systemic Light Chain Amyloidosis/Waldenström's Macroglobulinemia Panel.